IV lignocaine ‘superior to fentanyl’ in angiography: trial
Lignocaine circumvents the impairment of ticagrelor seen with opioid analgesia, cardiologist says
AusDoc brings you the latest news from the Cardiac Society of Australia and New Zealand virtual annual scientific meeting, CSANZ 2021.
Routine use of opioids for pain relief during certain coronary interventions might need to be reconsidered as lignocaine is likely a better alternative, CSANZ 2021 has heard.
In the LOCAL trial, 70 patients undergoing coronary angiography at the Alfred Hospital in Melbourne and indicated to receive ticagrelor were randomised to have analgesia with either IV fentanyl or IV lignocaine.
The impetus for the study was a bid to avoid the interaction that occurs between opioids and the P2Y12 inhibitor, ticagrelor, which reduces the effectiveness of the antiplatelet agent, the meeting was told.
